Issue 9, 2019

PVA reinforced gossypolone and doxorubicin π–π stacking nanoparticles towards tumor targeting and ultralow dose synergistic chemotherapy

Abstract

To improve the tumor synergistic therapeutic effects of carrier-free dual-drug delivery systems and realize ultralow dose administration, we developed a tumor targeting and high-efficiency synergistic chemotherapy system (HA-Gn@DPGn NPs) based on polyvinyl alcohol (PVA) reinforced gossypolone (Gn) and doxorubicin (DOX) π–π stacking nanoparticles (DPGn NPs), in which PVA filled the gaps between Gn and DOX and bridged Gn and DOX tightly. Hyaluronic acid modifier hyaluronic acid-gossypolone (HA-Gn) was covered on the surface of DPGn NPs to form HA-Gn@DPGn NPs that procured active targeting properties. This system presented a spherical shape with a uniform hydrodynamic size of 87 ± 6.8 nm, a high drug loading of 80.31%, and high stability. FTIR and UV spectra demonstrated that HA-Gn was covered on the surface of the system and showed significant π–π stacking properties. A considerably low combination index of Gn and DOX (0.1862) was determined at an ultra-low dose of DOX under a Gn : DOX ratio of 50 : 1. HA-Gn@DPGn NPs also demonstrated excellent tumor synergistic therapeutic efficacy (TIR > 87%) at an ultralow dose of DOX and Gn. This system demonstrates high tumor comprehensive synergistic therapeutic efficacy at an ultralow drug dose with multiple favorable therapeutic characteristics, including negligible side effects, tumor targeting ability and thermal-responsive drug release, and thus has considerable potential for tumor synergistic therapy.

Graphical abstract: PVA reinforced gossypolone and doxorubicin π–π stacking nanoparticles towards tumor targeting and ultralow dose synergistic chemotherapy

Supplementary files

Article information

Article type
Paper
Submitted
28 Apr 2019
Accepted
27 May 2019
First published
31 May 2019

Biomater. Sci., 2019,7, 3662-3674

PVA reinforced gossypolone and doxorubicin π–π stacking nanoparticles towards tumor targeting and ultralow dose synergistic chemotherapy

Y. Liu, K. Li, Y. Wu, J. Ma, P. Tang, Y. Liu and D. Wu, Biomater. Sci., 2019, 7, 3662 DOI: 10.1039/C9BM00674E

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements